ECSP056104A - Compuestos heterociclicos inmunomoduladores - Google Patents

Compuestos heterociclicos inmunomoduladores

Info

Publication number
ECSP056104A
ECSP056104A EC2005006104A ECSP056104A ECSP056104A EC SP056104 A ECSP056104 A EC SP056104A EC 2005006104 A EC2005006104 A EC 2005006104A EC SP056104 A ECSP056104 A EC SP056104A EC SP056104 A ECSP056104 A EC SP056104A
Authority
EC
Ecuador
Prior art keywords
immunomodulating
heterociclical
compounds
heterociclical compounds
solvate
Prior art date
Application number
EC2005006104A
Other languages
English (en)
Inventor
Ian Richard Mathews
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305876A external-priority patent/GB0305876D0/en
Priority claimed from GB0319429A external-priority patent/GB0319429D0/en
Application filed by Avidex Ltd filed Critical Avidex Ltd
Publication of ECSP056104A publication Critical patent/ECSP056104A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos de la fórmula (I) son inhibidores de CD80 y son útiles en la terapia de inmunomodulación: en donde R1 y R3 representan independientemente H; F; Cl; Br; -NO2; -CN; alquilo de 1 a 6 átomos de carbono sustituido opcionalmente por F o Cl; o alcoxi de 1 a 6 átomos de carbono sustituido opcionalmente por F; R4 representa un grupo de ácido carboxílico (-COOH) o un éster del mismo, o -C(=O)NR6R7, -NR7C(=O)R6, -NR7C(=O)OR6, -NHC(=O)NR7R6 o -NHC(=S)NR7R6, en donde R6 representa H, o un radical de la fórmula -(Alq)m-Q en donde m es 0 o 1, Alq es un radical de alquileno de 1 a 12 átomos de carbono o alquenileno de 2 a 12 átomos de carbono o alquinileno de 2 a 12 átomos de carbono de cadena recta o ramificada, divalente, sustituido opcionalmente o un radical carbocíclico de 3 a 12 átomos de carbono, divalente, cualquiera de estos radicales puede contener una o más uniones de -O-, -S- o -N(R8)-, en donde R8 representa H o alquilo de 1 a 4 átomos de carbono, alquenilo de 3 a 4 átomos de carbono, alquinilo de 3 a 4 átomos de carbono o cicloalquilo de 3 a 6 átomos de carbono y Q representa H; -NR9R10, en donde R9 y R10 representan independientemente H; alquilo de 1 a 4 átomos de carbono; alquenilo de 3 a 4 átomos de carbono; alquinilo de 3 a 4 átomos de carbono; cicloalquilo de 3 a 6 átomos de carbono; un grupo éster; un grupo carbocíclico o heterocíclico sustituido opcionalmente; o R9 y R10 forman un anillo cuando se toman junto con el átomo de nitrógeno al cual están unidos, anillo que es sustituido opcionalmente; y R7 representa H o alquilo de 1 a 6 átomos de carbono; o cuando se toma junto con el átomo o átomos a los cuales están unidos R6 y R7 forman un anillo heterocíclico, monocíclico, sustituido opcionalmente que tiene 5, 6 o 7 átomos del anillo; y X representa un enlace o un radical divalente de la fórmula -(Z)n-(Alq)- o -(Alq)-(Z)n- en donde Z representa -O-, -S- o -NH-, Alq es como se define con relación a R6 y n es 0 o 1.
EC2005006104A 2003-03-14 2005-10-14 Compuestos heterociclicos inmunomoduladores ECSP056104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0305876A GB0305876D0 (en) 2003-03-14 2003-03-14 Immuno inhibitory heterocyclic compounds
GB0319429A GB0319429D0 (en) 2003-08-19 2003-08-19 Immuno Inhibitory Heterocyclic compounds

Publications (1)

Publication Number Publication Date
ECSP056104A true ECSP056104A (es) 2006-03-01

Family

ID=32992598

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006104A ECSP056104A (es) 2003-03-14 2005-10-14 Compuestos heterociclicos inmunomoduladores

Country Status (19)

Country Link
US (3) US7276505B2 (es)
EP (2) EP2284172A1 (es)
JP (1) JP4892338B2 (es)
KR (1) KR101133959B1 (es)
AT (1) ATE489388T1 (es)
BR (1) BRPI0408365B8 (es)
CA (1) CA2519063C (es)
DE (1) DE602004030225D1 (es)
DK (1) DK1603917T3 (es)
EA (2) EA014080B1 (es)
EC (1) ECSP056104A (es)
IL (1) IL170389A (es)
MX (1) MXPA05009667A (es)
NO (1) NO332136B1 (es)
NZ (1) NZ541973A (es)
PL (2) PL1603917T3 (es)
PT (1) PT1603917E (es)
SI (1) SI1603917T1 (es)
WO (1) WO2004081011A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081011A1 (en) * 2003-03-14 2004-09-23 Avidex Limited Immunomodulating heterocyclic compounds
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
US7932253B2 (en) 2004-08-09 2011-04-26 Medigene Ag Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors
CA2618888A1 (en) * 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
GB0603522D0 (en) 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
EP1994022A2 (en) 2006-03-15 2008-11-26 Wyeth a Corporation of the State of Delaware N-substituted-azacyclylamines as histamine-3 antagonists
EP2027086B1 (en) 2006-05-19 2011-11-16 Wyeth LLC N-benzoyl-pyrrolidin-3-ylamines as histamine-3 antagonists
US20100093867A1 (en) * 2006-07-05 2010-04-15 Ryoichi Matsuda Method Of Treating Genetic Disease Caused By Nonsense Mutation
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
WO2009012252A1 (en) 2007-07-16 2009-01-22 Wyeth Aminoalkylazole derivatives as histamine-3 antagonists
EP2020404A1 (en) * 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
CN101815512B (zh) 2007-10-04 2013-04-24 弗·哈夫曼-拉罗切有限公司 环丙基芳基酰胺衍生物和其用途
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2676666A1 (en) 2012-06-20 2013-12-25 Eidgenössische Technische Hochschule Zürich (ETH) Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
JP2017528461A (ja) * 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 置換ピロリジンカルボキサミド化合物
JP7120549B2 (ja) * 2016-12-15 2022-08-17 小野薬品工業株式会社 Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB629412A (en) 1946-12-24 1949-09-20 Geigy Ag J R Manufacture of metallisable monoazo dyestuffs of the pyrazolone series
US3576637A (en) 1967-04-20 1971-04-27 Konishiroku Photo Ind Lith-type of emulsion containing pyrozolone
JPS61161285A (ja) * 1984-12-28 1986-07-21 ルセル−ユクラフ ピラゾロ〔４，３−ｃ〕シンノリン−３−オンの誘導体、それらの塩類、これらの製造法、薬剤としての使用、これらを含有する組成物及び中間体生成物
US4591589A (en) * 1985-01-16 1986-05-27 Roussel Uclaf 2-aryl pyrazolo[4,3-c]cinnolin-3-ones
DE3626221A1 (de) 1986-08-02 1988-02-04 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger aufsichtsbilder
US4906644A (en) 1986-11-20 1990-03-06 Mitsubishi Kasei Corporation Lipid-peroxide formation inhibiting composition and novel compounds useful therefor
DE3903993A1 (de) 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
AR006520A1 (es) * 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
GB9713707D0 (en) * 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
SE0102404D0 (sv) * 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
US7208495B2 (en) 2001-07-05 2007-04-24 Takeda Pharmaceutical Company Limited Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
RU2328496C2 (ru) 2002-11-22 2008-07-10 Эктив Байотек Аб Пиразолхинолины с иммуномодулирующей активностью
WO2004055014A1 (en) 2002-12-16 2004-07-01 Active Biotech Ab Tetracyclic immunomodulatory compounds
WO2004081011A1 (en) 2003-03-14 2004-09-23 Avidex Limited Immunomodulating heterocyclic compounds
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
US7932253B2 (en) 2004-08-09 2011-04-26 Medigene Ag Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors
US20060221590A1 (en) * 2005-03-31 2006-10-05 Edoardo Campini System and method for Advanced Mezzanine Card connection
GB0603522D0 (en) 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition

Also Published As

Publication number Publication date
EA009680B1 (ru) 2008-02-28
NO332136B1 (no) 2012-07-02
BRPI0408365B1 (pt) 2018-11-21
AU2004220310A1 (en) 2004-09-23
CA2519063C (en) 2011-05-10
US20080045527A1 (en) 2008-02-21
KR101133959B1 (ko) 2012-04-09
PT1603917E (pt) 2011-02-04
BRPI0408365A (pt) 2006-03-21
JP4892338B2 (ja) 2012-03-07
MXPA05009667A (es) 2006-01-27
DE602004030225D1 (de) 2011-01-05
NZ541973A (en) 2009-06-26
US7598247B2 (en) 2009-10-06
PL1603917T3 (pl) 2011-12-30
ATE489388T1 (de) 2010-12-15
EA014080B1 (ru) 2010-08-30
IL170389A (en) 2013-08-29
EA200702435A1 (ru) 2008-06-30
WO2004081011A1 (en) 2004-09-23
US20090312334A1 (en) 2009-12-17
EA200501370A1 (ru) 2006-08-25
EP1603917B1 (en) 2010-11-24
JP2006520372A (ja) 2006-09-07
HK1090921A1 (zh) 2007-01-05
EP2284172A1 (en) 2011-02-16
US7276505B2 (en) 2007-10-02
SI1603917T1 (sl) 2011-04-29
EP1603917A1 (en) 2005-12-14
BRPI0408365B8 (pt) 2021-05-25
NO20054710L (no) 2005-12-13
DK1603917T3 (da) 2011-02-28
CA2519063A1 (en) 2004-09-23
NO20054710D0 (no) 2005-10-13
PL383655A1 (pl) 2008-04-14
US20070021428A1 (en) 2007-01-25
US8309552B2 (en) 2012-11-13
KR20050121681A (ko) 2005-12-27

Similar Documents

Publication Publication Date Title
ECSP056104A (es) Compuestos heterociclicos inmunomoduladores
CY1107168T1 (el) Παραγωγα φαινυλοαλκανοϊκου οξεος και φαινυλοξυαλκανοϊκου οξεος ως ενεργοποιηται hppar
NL300927I9 (nl) Tivozanib of een zout, solvaat of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
GB2398781B (en) Kinase inhibitors
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
DE60319080D1 (de) Phenyloxyalkansäure-derivate als hppar aktivatore
WO2005074642A3 (en) Chemical compounds
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
DE602004031878D1 (de) Immunhemmende pyrazolon-verbindungen
GB0215392D0 (en) Chemical compounds
MXPA06004299A (es) Derivados de arilespirofuropiridina.
TW200518748A (en) Chemical compounds
WO2005068451A3 (en) Methods for the synthesis of dictyostatin and derivatives and analogues thereof, stereochemical characterisation, novel dictyostatin compounds and uses thereof and synthetic intermediates
WO2004103305A3 (en) Spiropyrazole compound
MXPA05005830A (es) Metodos para preparar derivados de fenilalquino.